Acute congestive heart failure due to Bevacizumab in metastatic breast cancer: about a case

被引：0

作者：

Akimana, Gloria ^{[1
]}

Onana, Remy ^{[1
]}

Lkhooyali, Samih ^{[1
]}

Errihani, Hassan ^{[1
]}

机构：

[1] Inst Natl Oncol, Serv Oncol Med, Rabat, Morocco

来源：

PAN AFRICAN MEDICAL JOURNAL | 2022年 / 43卷

关键词：

Metastatic breast; Bevacizumab; congestive heart failure; a case report; PHASE-III; EFFICACY; SAFETY;

D O I：

10.11604/pamj.2022.43.50.34743

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The addition of Bevacizumab to chemotherapy has shown its first-line interest in metastatic breast cancer by improving PFS but not OS. After a certain period of exposure, the appearance of side effects such as acute Congestive heart failure (CHF) has been described during clinical trials; manifested by a drop in LVEF and clinical signs which sometimes caused a hospitalization. We report the case of a patient in whom this exposure time was rather long with a very long survival under Bevacizumab. The onset of arterial hypertension appeared after 8 months of treatment with Bevacizumab in combination with metastatic first-line chemotherapy, while acute CHF occurred after approximately 10 years of treatment, which is at the 129th treatment. The evolution of CHF was favorable after adequate treatment and discontinuation of Bevacizumab as in most cases reported in the literature.

引用

页数：6

共 12 条

[1]

Dieras V, 2010, LETTRE CANCEROLOGUE, V19, P513

[2]

Electronic medicines compendium (emc), Summary of Product Characteristics: Jaydess 13.5 mg intrauterine delivery system

[3]

Evrard J, 2017, PHARMACIEN HOSPITALI, V52, P29

[4]

Halimi JM, 2004, NEPHROL THER, V4, P602

[5] Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population [J].